Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

HeartWare Schedules Third Quarter Conference Call And Webcast

        HeartWare Schedules Third Quarter Conference Call And Webcast

PR Newswire

FRAMINGHAM, Mass. and SYDNEY, Nov. 1, 2012

FRAMINGHAM, Mass. and SYDNEY, Nov. 1, 2012 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to
discuss its financial results for the three months ended September 30, 2012,
at 8:00 a.m. U.S. Eastern Standard Time on Friday, November 9, 2012. The
Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial
results, highlights from the third quarter and business outlook.  The call may
be accessed by dialing 1-877-941-1428 five minutes prior to the scheduled
start time and referencing "HeartWare."  For callers outside the U.S., please
dial +1-480-629-9665.

A live webcast of the call will also be available at the Company's website
( by selecting "HeartWare Third Quarter 2012 Conference
Call" under the section titled "Corporate Presentations" on the Home Page.  A
replay of the conference call will be available through the above weblink
immediately following completion of the call.

A copy of the news release announcing results and related information will be
available on the Company's website,

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure.  The HeartWare^® Ventricular Assist
System features the HVAD^® pump, a small full-output circulatory support
device designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices.  The HeartWare System
has received CE Marking in the European Union and TGA approval in Australia.
 The device is currently the subject of United States clinical trials for two
indications: destination therapy and bridge-to-transplant under a continued
access protocol.  For additional information, please visit the Company's
website at

HeartWare International, Inc. is a member of the Russell 2000^® and its
securities are publicly traded on The NASDAQ Stock Market and the Australian
Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864



SOURCE HeartWare International, Inc.

Sponsored Links
Sponsored Links